TICKERNERD
Menu
PSNLPSNLHealthcare · Diagnostics & Research

PSNL Stock Forecast: Personalis, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$17
+1.35% on the day

The 5 Wall Street analysts covering Personalis, Inc. hold a median 12-month price target of $16 — -1.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 23 Sept 2026 — in the lower half.

Market cap
$1.7B
Ticker Nerd rank
42 / 100
Median analyst target
$16
Analysts covering
5
Revenue$22.4M+30.0% y/y
Operating income−$33.6M
Net income−$31.7M
Free cash flow−$29.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.1%
1M
−2.9%
YTD
+108.2%
1Y
+173.4%
From 52W high
−9.8%
From 52W low
+228.8%
$5
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PSNL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Personalis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Revisions
57
Issuance
51
Value
44
Accruals
44
Growth
38
Size
38
Quality
36
Volatility
13

Momentum (98): The shares have been drifting up relative to others.

Volatility (13): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PSNL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PSNL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14$16$18Oct 25Jan 26Apr 26Jul 26PSNLHigh $16Median $16Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
2 Buy3 Hold0 Sell
Low $13Median $16High $16

The green dot is the last close — the median target sits −1.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 July 2026BTIGMaintainsBuy—
20 July 2026BTIGMaintainsBuy$11 → $16
20 July 2026Lake StreetDowngradeHold$16
20 July 2026Lake StreetDowngradeHold—
20 July 2026NeedhamDowngradeHold—
20 July 2026NeedhamDowngradeHold—
17 July 2026NeedhamMaintainsBuy$12 → $17
17 July 2026NeedhamMaintainsBuy—
9 July 2026Morgan StanleyMaintainsEqual-Weight—
12 May 2026Morgan StanleyMaintainsEqual-Weight—
11 May 2026BTIGMaintainsBuy—
5 Mar 2026Morgan StanleyMaintainsEqual-Weight—
27 Feb 2026NeedhamMaintainsBuy—
11 Feb 2026BTIGMaintainsBuy—
26 Jan 2026GuggenheimMaintainsBuy—
9 Jan 2026BTIGReiteratesBuy—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
11 Nov 2025BTIGMaintainsBuy—
11 Nov 2025GuggenheimMaintainsBuy—
11 Nov 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PSNL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PSNL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, Personalis, Inc. returned +173.4% against +17.3% for the S&P 500, dividends included.

PSNL vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26PSNLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PSNL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Personalis, Inc. (PSNL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−18.0×

Cheaper than 96% of US stocks

Price / sales
25.1×

Cheaper than 8% of US stocks

Price / book
7.4×

Cheaper than 13% of US stocks

EV / EBITDA
−15.0×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
30.0%

Higher than 78% of US stocks

Earnings growth (YoY)
—
Gross margin
21.2%

Higher than 23% of US stocks

Operating margin
−150.2%

Higher than 12% of US stocks

Net margin
−153.8%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−50.3%

Higher than 21% of US stocks

Return on assets
−25.0%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Personalis, Inc. (PSNL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Personalis, Inc. has a market value of $1.7B and an enterprise value of $1.6B.

  • Revenue in the twelve months to 30 June 2026: $69.7M. The latest quarter grew 30.0% year on year.

  • Net income over the same four quarters: −$107.2M, a −153.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.09.

  • Free cash flow in the twelve months to 30 June 2026: −$101.0M.

  • Shares outstanding: 106.4M.

  • Trailing P/E: −18.0×; forward P/E: −17.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Personalis, Inc. employs 259 people — $269K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Sept 2026

Data provided by Twelve Data

Peers

PSNL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
PSNLPersonalis, Inc.$1.7B
42
FRNMFreenome, Inc.$1.7B
32
OPKOPKO Health, Inc.$1.3B
82
NEONeoGenomics, Inc.$2.4B
77
WGSGeneDx Holdings Corp.$2.4B
46
CDNACareDx, Inc.$2.8B
99
CSTLCastle Biosciences, Inc.$1.0B
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Personalis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PSNL news & analysis

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)

GlobeNewsWire · 23 Sept 2026neutral

The law firm Brodsky & Smith issued a shareholder update announcing investigations into several companies, including Personalis, Inc. (Nasdaq – PSNL). Investors who own shares are invited to contact the firm at no cost to discuss the investigation.

Why it matters — PSNL watchers may want to be aware that an investor investigation has been announced concerning the company, though no specific allegations or findings are detailed in the notice.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

GlobeNewsWire · 9 Sept 2026negative

Brodsky & Smith issued a shareholder update reminding investors of investigations involving Personalis, Inc., along with Werewolf Therapeutics, Beazer Homes USA, and MarketAxess Holdings. The firm invites affected shareholders to contact them at no cost to discuss the investigation.

Why it matters — A PSNL watcher would care because the firm's reminder signals an active investigation into the company that shareholders may want to be aware of.

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 4 Aug 2026negative

Personalis reported a second-quarter loss of $0.30 per share, wider than the Zacks Consensus Estimate of a $0.25 loss and worse than the $0.23 loss a year prior. The headline indicates revenue topped estimates.

Why it matters — PSNL watchers track how the company's quarterly results compare with consensus estimates, and this quarter's loss came in wider than expected.

Personalis Reports Second Quarter Results and Recent Highlights

Business Wire · 4 Aug 2026positive

Personalis reported its second quarter 2026 financial results and highlighted recent operational achievements, including receiving Medicare coverage approval for NeXT Personal for immunotherapy monitoring in late-stage solid tumor patients.

Why it matters — Medicare coverage for NeXT Personal opens a key reimbursement pathway for Personalis' core product in a large patient population, which could drive adoption and revenue.

FAQ

Frequently asked questions about PSNL stock

What is the PSNL stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Personalis, Inc. have a median 12-month price target of $16, with estimates ranging from $13 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PSNL stock a buy right now?

Of the 5 analysts covering Personalis, Inc., 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Personalis, Inc. 42 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PSNL?

As at 23 Sept 2026, Personalis, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will PSNL stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies -1.9% from the last close, and Ticker Nerd's factor model ranks Personalis, Inc. 42 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PSNL stock forecast for 2030?

No analyst covering Personalis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PSNL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $16 over the next 12 months.

How has PSNL stock performed over the past year?

Personalis, Inc. returned +173.4% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Personalis, Inc. do?

Personalis Inc. is a biotechnology company focused on advanced cancer genomics and precision oncology.

What is the latest news on PSNL?

The most recent item we track (GlobeNewsWire, 23 Sept 2026): "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)". The law firm Brodsky & Smith issued a shareholder update announcing investigations into several companies, including Personalis, Inc. (Nasdaq – PSNL). Investors who own shares are invited to contact the firm at no cost to discuss the investigation.

Company

About Personalis, Inc.

Personalis Inc. is a biotechnology company focused on advanced cancer genomics and precision oncology. Personalis develops and markets genomic tests and sequencing services that help healthcare providers, pharmaceutical companies, biopharma partners, universities, and government organizations analyze tumor and immune-system signals. Its current offerings include liquid biopsy and molecular profiling solutions designed to detect minimal residual disease, monitor recurrence, and support therapy selection, along with sequencing and data analysis services for population-scale research programs. The company also provides platforms and assays used in immuno-oncology and personalized cancer vaccine development. Personalis serves customers primarily in the United States and Europe, with additional international reach through research and clinical applications. Headquartered in Fremont, California, Personalis plays an important role in translating complex genomic data into actionable insights for cancer research and patient management.

CEO Mr. Christopher M. Hall · 259 employees · United States · https://www.personalis.com